2018年 論文

  • No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T, Hongo H, Watanabe K, Mizuno R, Kikuchi E, Oya M.
    Cancer Chemother Pharmacol. 2018 Dec;82(6):1061-1066. doi: 10.1007/s00280-018-3698-1. Epub 2018 Oct 3.
  • Single-cell RNA-seq analysis reveals the platinum resistance gene COX7B and the surrogate marker CD63.
    Tanaka N, Katayama S, Reddy A, Nishimura K, Niwa N, Hongo H, Ogihara K, Kosaka T, Mizuno R, Kikuchi E, Mikami S, Miyakawa A, Arenas E, Kere J, Oya M, Uhlén P.
    Cancer Med. 2018 Dec;7(12):6193-6204. doi: 10.1002/cam4.1828. Epub 2018 Oct 26.
  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
    Ito K, Mikami S, Tatsugami K, Masumori N, Shinohara N, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T.
    Clin Genitourin Cancer. 2018 Dec;16(6):e1201-e1214. doi: 10.1016/j.clgc.2018.07.028. Epub 2018 Aug 11.
  • Aldosterone and 18-Oxocortisol Coaccumulation in Aldosterone-Producing Lesions.
    Sugiura Y, Takeo E, Shimma S, Yokota M, Higashi T, Seki T, Mizuno Y, Oya M, Kosaka T, Omura M, Nishikawa T, Suematsu M, Nishimoto K.
    Hypertension. 2018 Dec;72(6):1345-1354. doi: 10.1161/HYPERTENSIONAHA.118.11243.
  • Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
    Kojima T, Nishiyama H, Ozono S, Hinotsu S, Keino N, Yamaguchi A, Sakai H, Enomoto Y, Horie S, Fujimoto K, Matsuyama H, Okamura T, Kanimoto Y, Oya M, Nonomura N, Naito S, Akaza H.
    Int J Clin Oncol. 2018 Dec;23(6):1140-1147. doi: 10.1007/s10147-018-1311-6. Epub 2018 Jul 3.
  • Risk stratification of castration-resistant prostate cancer patients treated with cabazitaxel.
    Kosaka T, Hongo H, Mizuno R, Oya M.
    Mol Clin Oncol. 2018 Dec;9(6):683-688. doi: 10.3892/mco.2018.1724. Epub 2018 Sep 19.
  • Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA.
    Yanai Y, Kosaka T, Hongo H, Matsumoto K, Shinojima T, Kikuchi E, Miyajima A, Mizuno R, Mikami S, Jinzaki M, Oya M.
    Mol Clin Oncol. 2018 Dec;9(6):656-660. doi: 10.3892/mco.2018.1725. Epub 2018 Sep 19.
  • Rare association of the anterior and posterior urethral valves.
    Murakami T, Asanuma H, Shigeta K, Ezaki T, Oya M.
    Pediatr Int. 2018 Dec;60(12):1090-1091. doi: 10.1111/ped.13711. No abstract available.
  • Retrocaval Ureter Manifested after Ureteral Reimplantation for Ipsilateral Vesicoureteral Reflux: A Case Report.
    Katsui M, Asanuma H, Fukumoto K, Mizuno R, Oya M.
    Urol J. 2018 Nov 17;15(6):397-399. doi: 10.22037/uj.v0i0.4103.
  • Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.
    Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Tsukamoto T.
    Cancer Med. 2018 Oct;7(10):4893-4902. doi: 10.1002/cam4.1735. Epub 2018 Aug 27.
  • Pre-operative and post-operative estimated glomerular filtration rate in Japanese patients with urological malignancies.
    Niwa N, Yoshida T, Mizuno R, Kikuchi E, Miyajima A, Hayashi M, Oya M.
    Clin Exp Nephrol. 2018 Oct;22(5):1205-1212. doi: 10.1007/s10157-017-1509-3. Epub 2017 Nov 27.
  • History of Non-Muscle-Invasive Bladder Cancer May Have a Worse Prognostic Impact in cT2-4aN0M0 Bladder Cancer Patients Treated With Radical Cystectomy.
    Kayama E, Kikuchi E, Fukumoto K, Shirotake S, Miyazaki Y, Hakozaki K, Kaneko G, Yoshimine S, Tanaka N, Takahiro M, Kanai K, Oyama M, Nakajima Y, Hara S, Monma T, Oya M.
    Clin Genitourin Cancer. 2018 Oct;16(5):e969-e976. doi: 10.1016/j.clgc.2018.04.004. Epub 2018 Apr 28.
  • Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
    Hongo H, Kosaka T, Oya M.
    Cancer Sci. 2018 Sep;109(9):2937-2945. doi: 10.1111/cas.13729. Epub 2018 Aug 6.
  • Updated long-term outcomes after carbon-ion radiotherapy for primary renal cell carcinoma.
    Kasuya G, Tsuji H, Nomiya T, Makishima H, Haruyama Y, Kobashi G, Ebner DK, Hayashi K, Omatsu T, Kishimoto R, Yasuda S, Igarashi T, Oya M, Akakura K, Suzuki H, Ichikawa T, Shimazaki J, Kamada T; Working Group for Genitourinary Tumors.
    Cancer Sci. 2018 Sep;109(9):2873-2880. doi: 10.1111/cas.13727. Epub 2018 Sep 1.
  • Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.
    Fukumoto K, Kikuchi E, Mikami S, Hayakawa N, Matsumoto K, Niwa N, Oya M.
    Ann Surg Oncol. 2018 Aug;25(8):2484-2491. doi: 10.1245/s10434-018-6498-2. Epub 2018 May 1.
  • Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy. Takamatsu K, Mizuno R, Omura M, Morita S, Matsumoto K, Shinoda K, Kosaka T, Takeda T, Shinojima T, Kikuchi E, Asanuma H, Oyama M, Mikami S, Oya M.
    Clin Genitourin Cancer. 2018 Aug;16(4):e927-e933. doi: 10.1016/j.clgc.2018.03.012. Epub 2018 Mar 27.
  • Incidence and timing of inadvertent nephrostomy catheter displacement in patients with ureteral obstruction
    Niwa N, Matsumoto K, Kikuchi E, Yazawa S, Takeda T, Morita S, Kosaka T, Shinoda K, Mizuno R, Shinojima T, Asanuma H, Oya M.
    Clin Nephrol. 2018 Aug;90(2):112-116. doi: 10.5414/CN109294.
  • Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis.
    Tatsugami K, Oya M, Kabu K, Akaza H.
    Br J Cancer. 2018 Jul;119(2):241-247. doi: 10.1038/s41416-018-0129-3. Epub 2018 Jun 12.
  • Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.
    Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H.
    Mol Cancer Ther. 2018 Jul;17(7):1566-1574. doi: 10.1158/1535-7163.MCT-17-1061. Epub 2018 May 2.
  • Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K, Niwa N, Hattori S, Takeda T, Morita S, Kosaka T, Mizuno R, Shinojima T, Kikuchi E, Asanuma H, Oya M.
    Urol Oncol. 2018 Jul;36(7):341.e9-341.e14. doi: 10.1016/j.urolonc.2018.04.003. Epub 2018 May 3.
  • PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer.
    Yasumizu Y, Hongo H, Kosaka T, Mikami S, Nishimoto K, Kikuchi E, Oya M.
    Oncotarget. 2018 Jun 12;9(45):27698-27707. doi: 10.18632/oncotarget.25498. eCollection 2018 Jun 12.
  • Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
    Okuyama T, Sameshima S, Takeshita E, Yoshioka R, Yamagata Y, Ono Y, Tagaya N, Noie T, Oya M.
    World J Surg Oncol. 2018 Jun 5;16(1):105. doi: 10.1186/s12957-018-1403-9.
  • Prognostic Value of Pretreatment Albumin-to-Globulin Ratio in Patients With Non-Muscle-Invasive Bladder Cancer.
    Niwa N, Matsumoto K, Ide H, Nagata H, Oya M.
    Clin Genitourin Cancer. 2018 Jun;16(3):e655-e661. doi: 10.1016/j.clgc.2017.12.013. Epub 2018 Jan 4.
  • Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).
    Kosugi C, Koda K, Ishibashi K, Yoshimatsu K, Tanaka S, Kato R, Kato H, Oya M, Narushima K, Mori M, Shuto K, Ishida H.
    Int J Colorectal Dis. 2018 Jun;33(6):809-817. doi: 10.1007/s00384-018-2979-9. Epub 2018 Feb 27.
  • Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    J Urol. 2018 Jun;199(6):1446-1451. doi: 10.1016/j.juro.2017.12.057. Epub 2018 Jan 4.
  • Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non-muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy? Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    Urol Oncol. 2018 Jun;36(6):306.e1-306.e8. doi: 10.1016/j.urolonc.2018.02.005. Epub 2018 Mar 9.
  • Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.
    Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.
    J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.
  • Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
    Nishimura S, Ohashi T, Momma T, Sakayori M, Eriguchi T, Tanaka T, Yamashita S, Kosaka T, Oya M, Shigematsu N.
    Cancer Med. 2018 May;7(5):1794-1801. doi: 10.1002/cam4.1443. Epub 2018 Mar 25.
  • Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
    Kosaka T, Shinojima T, Morita S, Oya M.
    Cancer Sci. 2018 May;109(5):1570-1575. doi: 10.1111/cas.13556. Epub 2018 Apr 10.
  • Change of the 5α/5β ratio of urinary steroid metabolites in benign prostatic hyperplasia patients treated with dutasteride.
    Maeda T, Kikuchi E, Hasegawa M, Homma K, Yasumizu Y, Hattori S, Kosaka T, Shinoda K, Miyajima A, Oya M.
    Clin Biochem. 2018 May;55:36-41. doi: 10.1016/j.clinbiochem.2018.03.021. Epub 2018 Mar 31.
  • Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment.
    Tatsugami K, Oya M, Kabu K, Akaza H.
    Oncotarget. 2018 Apr 10;9(27):19406-19414. doi: 10.18632/oncotarget.24779. eCollection 2018 Apr 10.
  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.
    N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
  • [Continuation of Axitinib for Advanced Renal Cell Carcinoma by The Application of Homecare Urology - A Case Report and Literature Review].
    Yazawa S, Kato Y, Nakahara J, Miyata T, Oya M.
    Gan To Kagaku Ryoho. 2018 Apr;45(4):639-642. Japanese.
  • Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.
    Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.
  • Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    Anno T, Kikuchi E, Fukumoto K, Ogihara K, Oya M.
    Can Urol Assoc J. 2018 Mar;12(3):E132-E136. doi: 10.5489/cuaj.4786. Epub 2017 Dec 22.
  • Laparoscopic surgery to remove a cage that migrated to the retroperitoneal space during posterior lumbar interbody fusion: A case report.
    Okuyama T, Tagaya N, Sugamata Y, Hirano K, Saito K, Yamagata Y, Sameshima S, Noie T, Oya M.
    Asian J Endosc Surg. 2018 Feb;11(1):75-78. doi: 10.1111/ases.12400. Epub 2017 Jul 13.
  • Guidelines for treatment of renal injury during cancer chemotherapy 2016.
    Horie S, Oya M, Nangaku M, Yasuda Y, Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka C, Takaishi H, Shimodaira H, Mogi A, Ando Y, Matsumoto K, Kadowaki D, Muto S.
    Clin Exp Nephrol. 2018 Feb;22(1):210-244. doi: 10.1007/s10157-017-1448-z. Review. No abstract available.
  • Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guérin therapy.
    Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    Urol Oncol. 2018 Feb;36(2):77.e15-77.e21. doi: 10.1016/j.urolonc.2017.10.005. Epub 2017 Oct 31.
  • Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
    Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H, Oya M.
    BMC Cancer. 2018 Jan 31;18(1):113. doi: 10.1186/s12885-018-3988-3.
  • Selection of patients who would not require long-term prostate-specific antigen monitoring after low-dose-rate brachytherapy.
    Niwa N, Matsumoto K, Nishiyama T, Yagi Y, Ozu C, Nakamura K, Saito S, Oya M.
    Brachytherapy. 2018 Nov - Dec;17(6):899-905. doi: 10.1016/j.brachy.2018.08.018. Epub 2018 Sep 21.
  • Performance of diffusion-weighted MRI post-CT urography for the diagnosis of upper tract urothelial carcinoma: Comparison with selective urine cytology sampling.
    Akita H, Kikuchi E, Hayakawa N, Mikami S, Sugiura H, Oya M, Jinzaki M.
    Clin Imaging. 2018 Nov - Dec;52:208-215. doi: 10.1016/j.clinimag.2018.08.012. Epub 2018 Aug 16.
  • The Role of PD-1 Positivity in the Tumour Nest on Clinical Outcome in Upper Tract Urothelial Carcinoma Patients Treated with Radical Nephroureterectomy.
    Hayakawa N, Kikuchi E, Mikami S, Fukumoto K, Oya M.
    Clin Oncol (R Coll Radiol). 2018 Jan;30(1):e1-e8. doi: 10.1016/j.clon.2017.10.019. Epub 2017 Nov 15.
  • Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.
    Maeda T, Kikuchi E, Hasegawa M, Homma K, Ando T, Suzuki K, Kaneko G, Mizuno R, Miyajima A, Oya M.
    Int J Urol. 2018 Jan;25(1):70-74. doi: 10.1111/iju.13470. Epub 2017 Oct 3.
  • Publisher Correction: Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity.
    Tanaka N, Kanatani S, Tomer R, Sahlgren C, Kronqvist P, Kaczynska D, Louhivuori L, Kis L, Lindh C, Mitura P, Stepulak A, Corvigno S, Hartman J, Micke P, Mezheyeuski A, Strell C, Carlson JW, Fernández Moro C, Dahlstrand H, Östman A, Matsumoto K, Wiklund P, Oya M, Miyakawa A, Deisseroth K, Uhlén P.
    Nat Biomed Eng. 2018 Jan;2(1):48. doi: 10.1038/s41551-017-0162-1.